bluebird bio, Inc. is a leading biotechnology company based in Somerville, MA, dedicated to developing curative gene therapies for patients and their families. With a focus on diseases such as Beta-Thalassemia, Cerebral Adrenoleukodystrophy, and Sickle Cell Disease, bluebird bio is committed to providing innovative solutions through their one-time gene therapy treatments. Their proprietary lentiviral vector gene therapies aim to deliver functional copies of genes to a patient's own cells, setting a new standard in the field of gene therapy.
For over a decade, bluebird bio has been at the forefront of gene therapy advancements, leveraging the largest and deepest ex-vivo gene therapy data set in the world. Their approach involves collaboration, learning from the realities of others, and engaging in conversations that shape their actions and intentions. By pursuing a different approach to treating diseases and building platforms with broad therapeutic potential, bluebird bio is dedicated to delivering more "bluebird days" for patients and their families.
Generated from the website